The enrollment completion is a positive operational signal, but the data delay to Q1 2027 pushes the next binary catalyst further out. Monitor for any early biomarker or safety disclosures in the interim, and watch for the FSHD trial initiation in Q4 2026 as a secondary catalyst.
Price Chart
Executive Summary
Satellos Bioscience announced completion of enrollment in its BASECAMP Phase 2 trial of forazapadin for Duchenne muscular dystrophy, surpassing the target in under nine months. The company delayed topline data release to Q1 2027 (from a prior undisclosed timeline), citing a desire to compile a more complete dataset. This is a clinical milestone with no efficacy or safety data yet, and the delay introduces uncertainty.
Key Facts
- Enrollment completed for BASECAMP Phase 2 trial of forazapadin in ambulatory boys 7-10 with DMD, exceeding target in <9 months.
- Trial randomized 1:1:1 to forazapadin 60 mg, 120 mg, or placebo across 18 global sites.
- Topline clinical data now expected in Q1 2027, delayed from a prior undisclosed plan.
- Primary endpoints: safety, tolerability, and muscle force via dynamometry.
- Phase 2 FSHD study expected to begin Q4 2026.
Financial Impact
No financial figures disclosed; pre-revenue clinical-stage company.
Risk Factors
- Data delay introduces uncertainty and may disappoint investors expecting earlier readout.
- Phase 2 data may not support accelerated approval pathway; efficacy/safety remain unproven.
- Pre-revenue company with no approved products; dependent on future financing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006303 |
| Document: f6k_092926.htm | 0001171843-26-006303 |
| Document: 0001171843-26-006303-index-headers.html | 0001171843-26-006303 |
| Document: 0001171843-26-006303-index.html | 0001171843-26-006303 |
| Document: 0001171843-26-006303.txt | 0001171843-26-006303 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.54 (+1.87%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.54 (−2.39%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.54 (−18.76%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.54 (−23.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.54 (−24.91%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.54 (−30.13%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.54 (−34.73%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.54 (−27.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers